Conditions · Alzheimer's disease & early-stage dementia

Alzheimer's disease & early-stage dementia — frontier options in Oregon

11 open options

TRIALPHASE3RECRUITING
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
No Intervention — 212 sites
TRIALNARECRUITING
A Study of Dual-task Exercise Training to Prevent Falls Among Older Adults With Mild Cognitive Impairment
dual-task tai ji quan · standard tai ji quan · stretching — 1 site
TRIALNARECRUITING
Home Sleep Therapy for Older Adults With MCI
Transcranial Electrical Stimulation — 2 sites
TRIALPHASE2RECRUITING
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
LHP588 · LHP588 · Placebo Drug — 40 sites
TRIALPHASE3RECRUITING
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Acoramidis · Placebo oral tablet — 104 sites
TRIALPHASE2RECRUITING
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Donanemab · Placebo — 72 sites
TRIALPHASE2 / PHASE3RECRUITING
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
EXV-802 · Placebo · EXV-801 — 49 sites
TRIALPHASE2RECRUITING
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
VHB937 · VHB937 · Placebo — 74 sites
TRIALPHASE1RECRUITING
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
Centella asiatica product · Placebo — 1 site
TRIALPHASE3RECRUITING
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Trontinemab · Placebo — 150 sites
TRIALPHASE3RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
KarXT · KarX-EC · Placebo — 119 sites

Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗

Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.